Hong Kong Med J 2016 Aug;22(4):327–33 | Epub 17 Jun 2016
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
Impact of 18FDG PET and 11C-PIB PET brain imaging on the diagnosis of Alzheimer’s disease and other dementias in a regional memory clinic in Hong Kong
YF Shea, MRCP, FHKAM (Medicine)1; Joyce Ha, BSc1; SC Lee, BHS (Nursing)1; LW Chu, MD, FRCP1,2
1 Division of Geriatrics, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong
2 The Alzheimer’s Disease Research Network, SRT Ageing, The University of Hong Kong, Pokfulam, Hong Kong
Corresponding author: Dr YF Shea (email@example.com)
Objective: This study investigated the improvement in the accuracy of diagnosis of dementia subtypes among Chinese dementia patients who underwent [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography (18FDG PET) with or without carbon 11–labelled Pittsburgh compound B (11C-PIB).
Methods: This case series was performed in the Memory Clinic at Queen Mary Hospital, Hong Kong. We reviewed 109 subjects (56.9% were female) who received PET with or without 11C-PIB between January 2007 and December 2014. Data including age, sex, education level, Mini-Mental State Examination score, Clinical Dementia Rating scale score, neuroimaging report, and pre-/post-imaging clinical diagnoses were collected from medical records. The agreement between the initial and post-PET with or without 11C-PIB dementia diagnosis was analysed by the Cohen’s kappa statistics.
Results: The overall accuracy of initial clinical diagnosis of dementia subtype was 63.7%, and diagnosis was subsequently changed in 36.3% of subjects following PET with or without 11C-PIB. The rate of accurate initial clinical diagnosis (compared with the final post-imaging diagnosis) was 81.5%, 44.4%, 14.3%, 28.6%, 55.6% and 0% for Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia, vascular dementia, other dementia, and mixed dementia, respectively. The agreement between the initial and final post-imaging dementia subtype diagnosis was only fair, with a Cohen’s kappa of 0.25 (95% confidence interval, 0.05-0.45). For the 21 subjects who underwent 11C-PIB PET imaging, 19% (n=4) of those with Alzheimer’s disease (PIB positive) were initially diagnosed with non–Alzheimer’s disease dementia.
Conclusions: In this study, PET with or without 11C-PIB brain imaging helped improve the accuracy of diagnosis of dementia subtype in 36% of our patients with underlying Alzheimer’s disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
New knowledge added by this study
- Positron emission tomography (PET) with or without Pittsburgh compound B (PIB) brain imaging helps improve the accuracy of dementia subtype diagnosis in Chinese patients.
- PET with or without PIB brain imaging should be considered in patients with dementia who attend the memory clinic, especially if there is diagnostic difficulty.
With ageing of the world’s population, the prevalence of dementia increases: 46.8 million people worldwide were living with dementia in 2015. This is projected to reach 74.7 million in 2030 and 131.5 million in 2050, with 60% suffering from Alzheimer’s disease (AD).1 In Hong Kong, the prevalence of mild dementia has been reported to be 8.9% for adults aged 70 years or over, with 64.6% suffering from AD.2 Appropriate management of demented patients begins with correct diagnosis of dementia subtype that allows earlier implementation of disease-specific treatment. In particular, cholinesterase inhibitors (ChEIs) or N-methyl-D-aspartate receptor antagonists are mostly suitable for the treatment of AD. The current clinical diagnostic guidelines for various types of dementia have limited sensitivities and specificities, however. The sensitivity and specificity of clinical diagnostic criteria for AD, dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD) have been reported as 81% and 70%, 50% and 80%, 85% and 95%, respectively.3 4 5 6 In the most recent diagnostic criteria for AD, additional use of biomarkers of AD has been recommended by the National Institute on Aging and Alzheimer’s Association to improve the accuracy of AD diagnosis.3 Biomarkers for the diagnosis of AD include cerebrospinal fluid (CSF), amyloid pathological imaging (eg carbon 11–labelled Pittsburgh compound B [11C-PIB] positron emission tomography [PET]), and functional imaging (eg [18F]-2-fluoro-2-deoxy-D-glucose [18F-FDG] PET) that yield sensitivities and specificities of at least 90% and 85%, respectively in the diagnosis of AD, DLB, and FTD.3 7 8 9 10 11 Because of the invasive nature of lumbar puncture in the collection of CSF, neuroimaging modalities such as 18F-FDG PET and 11C-PIB PET are more accepted in routine clinical practice to improve the diagnosis of dementia subtype.
The most common functional neuroimaging is with 18F-FDG12 and the most common pathological neuroimaging is with 11C-PIB.13 These molecular imaging markers are imaged using PET. The 18F-FDG measures metabolic activity of the brain; 18F-FDG PET distinguishes well between AD and non-AD dementia.11 In a systematic review, the sensitivity and specificity for 18F-FDG PET in distinguishing between AD and DLB was 83%-99% and 71%-93%, respectively; and the sensitivity and specificity for 18F-FDG PET in distinguishing between AD and FTD was 97.6%-99% and 65%-86%, respectively.11 In the same systematic review, 18F-FDG PET predicted patients with mild cognitive impairment (MCI) deteriorating into dementia with sensitivity and specificity of 81%-82% and 86%-90%, respectively.11 Besides, 11C-PIB can detect the presence of fibrillar amyloid plaques that are a neuropathological marker of AD.13 Correlation studies with neuropathology have shown a sensitivity of 90% and specificity of 100%; 11C-PIB can reasonably distinguish AD from other types of dementia, eg FTD.13 Using neuropathology as the gold standard, the sensitivity and specificity was 89% and 83%, respectively.13 The presence of 11C-PIB retention also predicts the progression of patients with MCI: 50% progress to AD in 1 year and 80% progress to AD within 3 years.14
Previous studies with 18F-FDG and 11C-PIB PET have focused on highly selected diagnostic groups, and only a few studies have studied their impact in the routine clinical setting of a memory clinic at a tertiary university hospital. The latter are referral centres, and often encounter patients with complicated diagnostic issues. Ossenkoppele et al15 reported a cohort of 145 patients who underwent 18F-FDG and 11C-PIB PET after clinical assessment. Change in clinical diagnosis was required in 23% with the diagnostic confidence increased from a mean of 71% to 87%. Diagnosis remained unchanged in 96% after PET over the next 2 years.15 In seven patients with MCI and positive amyloid deposition on 11C-PIB PET, six progressed to AD during follow-up (5 had AD pattern of hypometabolism on 18F-FDG PET).15 In a retrospective study of 94 patients with MCI or dementia, Laforce et al16 showed that 18F-FDG PET brain scan led to a change in diagnosis in 29% of patients, and reduced the frequency of atypical or unclear diagnoses from 39.4% to 16%.
To the best of our knowledge, there are no published data on the impact of molecular neuroimaging on accuracy of diagnosis of AD or other dementias in the Chinese population. We hypothesised that brain 18F-FDG with or without 11C-PIB PET imaging can improve the accuracy of diagnosis of common dementia subtypes in a memory clinic. The objective of this study was to investigate the impact of brain 18F-FDG with or without 11C-PIB imaging in improving the accuracy of diagnosis of dementia subtype in a local memory clinic in Hong Kong.
This was a retrospective study conducted at the Memory Clinic of Queen Mary Hospital, the University of Hong Kong. Patients were referred by general practitioners, neurologists, geriatricians, surgeons, or psychiatrists. All patient records between January 2007 and December 2014 were reviewed. Inclusion criteria were a clinical diagnosis of MCI, dementia of any type, or unclassifiable dementia; and 18F-FDG with or without 11C-PIB PET performed within 3 months after the initial clinical diagnosis. The initial clinical assessment was performed by a geriatrician experienced in dementia care and included detailed history taking from primary carers of the patient, physical examination, cognitive assessment, and laboratory studies (including thyroid function test, vitamin B12 level, folate level, and syphilis serology [Venereal Disease Research Laboratory]). Clinical criteria for AD, FTD, DLB, and vascular dementia (VaD) were employed to establish the clinical diagnosis initially, without using any biomarker. The diagnosis of different dementia subtype before neuroimaging was based on the respective diagnostic guidelines. Patients with AD were diagnosed according to the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer’s Disease and Related Disorders Association) diagnostic criteria.17 Patients with DLB were diagnosed by the McKeith criteria.4 Behavioural variant (bv) of FTD was diagnosed by revised diagnostic criteria reported by the International bvFTD Criteria Consortium5 and language variant of FTD was diagnosed by latest published criteria.6 Patients with VaD were diagnosed according to the criteria of the NINDS-AIREN (National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l’Enseignement en Neurosciences).18 In this study, we reviewed the medical records of eligible subjects and collected data including age, sex, education level, Mini-Mental State Examination score, Clinical Dementia Rating scale score, molecular imaging report including the standardised uptake value ratio (SUVR) of 11C-PIB PET, and the pre- and post-imaging diagnoses. For patients who were diagnosed with MCI, their progression during subsequent follow-up visits was also reviewed.
The need for 18F-FDG with or without 11C-PIB PET was determined by the geriatrician who performed the initial clinical assessment. The images were evaluated by a radiologist with more than 10 years of experience in reading PET scans. Dementias were classified using the generally accepted criteria. Patients were fasted for at least 4 hours before the PET. The serum glucose level was measured in all patients. For 18F-FDG PET, the patient was rested in a dimly lit room with eyes closed for 30 minutes prior to injection of 18F-FDG via a venous catheter. Another 30 minutes of rest was observed before starting the acquisition. The acquired data were semi-quantitatively compared with age-stratified normal controls using three-dimensional stereotactic surface projections. For PIB imaging, acquisition was performed at 5 minutes and 35 minutes after 11C-PIB injection via a venous catheter, and SUVR images of 11C-PIB between 5 and 35 minutes were generated. Cerebellar grey matter was chosen as reference tissue. In this study, 11C-PIB PET scans were rated as positive (PIB+; if binding occurred in more than one cortical brain region; ie frontal, parietal, temporal, or occipital) or negative (PIB–; if predominantly white matter binding).
The pattern of 18F-FDG PET hypometabolism that is suggestive of each subtype of dementia is as follows6 12 19:
(1) AD—uni- or bi-lateral parietotemporal hypometabolism with posterior cingulate gyrus involvement or bilateral parietal and precuneal hypometabolism.
(2) DLB—same as AD with added hypometabolism in occipital lobes.
(3) bvFTD—uni- or bi-lateral frontotemporal hypometabolism with or without less-severe parietal hypometabolism.
(4) Semantic dementia—anterior temporal lobe hypometabolism.
(5) Progressive non-fluent aphasia—left posterior frontoinsular hypometabolism.
(6) VaD—well-defined focal defects not fitting the above described patterns.
Descriptive statistics were used for data analyses. Continuous variables were expressed as mean ± standard deviation or median (interquartile range) as appropriate. Categorical data were expressed as number and percentages. The agreement between pre- or post-imaging diagnoses of dementia subtype was analysed by the Cohen’s kappa (κ) statistic. The Cohen’s κ reflected the degree of agreement: <0 = no agreement, 0-0.20 = slight agreement, 0.21-0.40 = fair agreement, 0.41-0.60 = moderate agreement, 0.61-0.80 = substantial agreement, and 0.81-1.00 = almost perfect agreement. All analyses were performed with the Statistical Package for the Social Sciences (Windows version 18.0; SPSS Inc, Chicago [IL], US).
A total of 109 patients (56.9% were female) were recruited of whom 102 had dementia and seven had MCI. Both 18F-FDG and 11C-PIB PET data were available for 45 (41.3%) patients, and 64 patients underwent 18F-FDG only. The final diagnosis of the 102 demented patients after neuroimaging is shown in Table 1.
Table 1. Characteristics of demented patients by final diagnoses after brain 18F-FDG with or without 11C-PIB imaging (n=102)
The accuracy of clinical diagnoses is summarised in Table 2. Overall, PET scans confirmed the clinical impression in 63.7% of patients, and corrected the diagnosis in 36.3%. Using the result of PET scan as the gold standard, the frequency of accurate initial clinical diagnosis was low for FTD, VaD, and mixed dementia (14.3%, 28.6%, and 0%, respectively). The accuracy of clinical diagnosis for AD and DLB was 81.5% and 44.4%, respectively. After excluding subjects with an initial MCI diagnosis, the agreement between the initial and final post-imaging dementia diagnosis was only fair, with a Cohen’s κ of 0.25 (95% confidence interval, 0.05-0.45).
Table 2. Change in clinical diagnoses of dementia subtypes after 18F-FDG with or without 11C-PIB brain imaging
Table 3 lists the diagnosis of subjects before and after the availability of 18F-FDG with or without 11C-PIB PET neuroimaging. For subjects with a final diagnosis of AD (n=65), 18.5% (n=12) were initially diagnosed with non-AD dementia (including 3 with DLB, 2 with FTD, 4 with VaD, and 3 with other dementia) and subsequently received symptomatic AD therapy (ie ChEIs and/or memantine). For the 21 subjects who underwent PIB PET imaging, 19% (n=4) of those with AD (PIB+) were initially diagnosed with non-AD dementia. For subjects with an initial diagnosis of AD (n=74), 28.4% (n=21) had a change in diagnosis (including 4 DLB, 6 FTD, 4 VaD, 3 mixed AD plus VaD, and 4 with other dementia). Excluding subjects with DLB and mixed AD plus VaD, 13.7% of all subjects (14 out of 102) had discontinued their previous symptomatic AD therapy. For subjects with a final diagnosis of FTD (n=7), 85.7% (n=6) were initially misdiagnosed as AD. For subjects with a final diagnosis of DLB (n=9), 44.4% (n=4) were misdiagnosed as AD.
Five patients were diagnosed with unclassifiable dementia following neuroimaging, which comprised four females and one male with a mean age of 78 ± 9.4 years. All presented with amnesia. In addition, one patient presented with apraxia and dysexecutive syndrome and another presented with hyperorality. All of them were PIB-. An AD pattern of hypometabolism was present in four patients (2 with hypometabolism in posterior cingulate gyrus and 2 with hypometabolism in temporoparietal lobes). Isolated hypometabolism in the temporal lobes was present in one patient.
The clinical information of the seven amnesic MCI subjects are summarised in Table 4. None of the three subjects without imaging risk factors for AD deteriorated over a follow-up period of 1 to 5 years. Of the four amnesic MCI subjects with imaging risk factors, two deteriorated into AD over a follow-up period of 5 years.
In this study, we showed that 18F-FDG with or without 11C-PIB PET clarified and improved the accuracy of dementia diagnosis in 36.3% of patients, and confirmed the initial diagnosis in 63.7%. Using the results of PET scan as the gold standard, the accuracy of clinical diagnosis was low for FTD, VaD, and mixed dementia collectively. On the one hand, 11.7% of patients (ie 12 out of 102) were started on symptomatic AD therapy after the 18F-FDG with or without 11C-PIB PET neuroimaging investigations. On the other hand, 13.7% of patients (ie 14 out of 102) discontinued symptomatic AD therapy after 18F-FDG with or without 11C-PIB PET because they did not have AD.
We also showed that the accuracy of clinical diagnosis of DLB and FTD was low (44.4% and 14.3%, respectively). This finding was in agreement with a previous study.20 Both DLB and FTD are commonly misdiagnosed clinically as AD (50% for DLB and 85.7% for FTD).20 We have previously reported that 100% of our patients with biomarkers that confirmed DLB and FTD presented with memory impairment in our memory clinic.20 A previous study also reported that 26% of DLB patients were initially misdiagnosed with AD, and 57% of these DLB patients presented with memory impairment.21 We understand that an accurate diagnosis of DLB is very important for subsequent management. Patients with DLB are particularly sensitive to neuroleptics.21 Neuroleptic sensitivity can present as drowsiness, confusion, abrupt worsening of parkinsonism, postural hypotension, or neuroleptic malignant syndrome.21 Other clinical features of DLB that need to be observed and tackled include well-formed visual hallucinations, rapid eye movement sleep behavioural disorder, and autonomic symptoms (including postural hypotension, sialorrhoea, and urinary and bowel symptoms).21 By accurately establishing the diagnosis of DLB, careful observation of classic DLB symptoms may reduce unnecessary investigations. Regarding therapeutic implications, DLB is characterised by far greater cholinergic deficits than AD. Hence, most DLB patients will benefit from ChEIs, and the extent of symptomatic improvement should be monitored after such therapy.22
Similarly, FTD may be misdiagnosed as AD. The former can also present initially with memory impairment, as illustrated by our FTD patients. There is increasing evidence that elderly patients with FTD often present with memory impairment.5 23 24 In one autopsy study, 64% (n=7) of 11 elderly patients with FTD had anterograde memory loss.23 Current treatment guidelines do not advise giving ChEIs or memantine treatments to FTD patients. Thus, such medications should be stopped to prevent unnecessary adverse effects.25
In the past few years, disease-modifying treatments (eg bapineuzumab) have failed to demonstrate their efficacy in clinical trials with AD patients.26 Detailed post-hoc analyses with AD biomarkers have shown the problem of diagnosing AD in subjects recruited in these studies. Only approximately 80% of these subjects had AD amyloid pathology, according to the presence of amyloid PET scan.26 Thus, including 11C-PIB PET to confirm brain amyloid in study inclusion criteria can help ensure recruitment of genuine AD patients to future clinical trials of disease-modifying treatments for AD.27 Given the minimally invasive nature of 11C-PIB PET compared with CSF amyloid-beta (Aβ) 42 measurements,7 it is likely to be a more acceptable choice for patients in clinical trials. At present, there are ongoing clinical trials of AD treatments including secretase inhibitors, Aβ aggregation inhibitors, Aβ and tau immunotherapy.27 We believe that 11C-PIB PET will play an important role in these clinical trials.
It is considered that 18F-FDG and 11C-PIB PET may detect underlying AD in patients with MCI.28 In the present study, 50% of MCI patients (ie 2 out of 4) with 18F-FDG and 11C-PIB PET imaging findings positive for AD showed deterioration over a follow-up period of 5 years. Although recommending PET brain imaging in MCI patients is still debatable, we believe that this investigation can help clinicians to better plan future and long-term treatments. In particular, disease-modifying drugs for AD or MCI due to AD may prove to be effective in the coming decade. Finally, in the present study, five patients were diagnosed with unclassifiable dementia. In the four patients with an AD pattern of hypometabolism, AD may still be present as they may have diffuse plaques or amorphous plaques that do not bind well to PIB. Alternatively they may have another type of dementia that requires pathological confirmation, eg argyrophilic grain disease or neurofibrillary tangle–only dementia.29 We will follow up the remaining patient with isolated hypometabolism in the temporal lobes to see whether additional FTD features develop.
There were several limitations to the present study. This was a retrospective case series and as such we were unable to collect further information such as the pre-imaging or post-imaging confidence of diagnosis. The diagnosis of dementia relied on the clinical diagnostic criteria without pathological confirmation. Therefore, we were also unable to compare the relative accuracy of clinical diagnosis and PET diagnosis with pathological diagnosis. For patients with MCI, some were not followed up for sufficiently long to ascertain whether or not they had deteriorated and developed dementia. Structural imaging (including computed tomography or magnetic resonance imaging) of the brain was not analysed as a separate variable but integrated into the pre-functional imaging clinical diagnoses of dementia subtypes. Our case series is likely to have selection bias as PET imaging is mostly a self-paid service in Hong Kong. The exception is for patients who are retired civil servants or recipients of Comprehensive Social Security Assistance. Demented patients who could not afford PET may differ to the patients selected. Although the PET images were analysed and read by radiologists experienced in PET, the interpretations depended heavily on individual experience and training; also, radiologists were not blinded to clinical information written on the request form. Despite these limitations, our study should be more reflective of day-to-day practice in a memory clinic and how 18F-FDG with or without11C-PIB PET imaging may assist clinical diagnosis.
In this study, 18F-FDG with or without 11C-PIB brain imaging improved the accuracy of diagnosis of dementia subtype in 36% of patients with underlying AD, DLB, VaD, and FTD who presented to our memory clinic.
All authors have disclosed no conflicts of interest.
1. Alzheimer’s Disease International World Alzheimer Report 2015: executive summary. Available from: http://www.alz.co.uk/research/WorldAlzheimerReport2015-sheet.pdf. Accessed Sep 2015.
2. Lam LC, Tam CW, Lui VW, et al. Prevalence of very mild and mild dementia in community-dwelling older Chinese people in Hong Kong. Int Psychogeriatr 2008;20:135-48. Crossref
3. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:263-9. Crossref
4. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-72. Crossref
5. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-77. Crossref
6. Harris JM, Gall C, Thompson JC, et al. Classification and pathology of primary progressive aphasia. Neurology 2013;81:1832-9. Crossref
7. Shea YF, Chu LW, Zhou L, et al. Cerebrospinal fluid biomarkers of Alzheimer’s disease in Chinese patients: a pilot study. Am J Alzheimers Dis Other Demen 2013;28:769-75. Crossref
8. Duits FH, Teunissen CE, Bouwman FH, et al. The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean? Alzheimers Dement 2014;10:713-723.e2. Crossref
9. Sinha N, Firbank M, O’Brien JT. Biomarkers in dementia with Lewy bodies: a review. Int J Geriatr Psychiatry 2012;27:443-53. Crossref
10. Harris JM, Gall C, Thompson JC, et al. Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia. Neurology 2013;80:1881-7. Crossref
11. Davison CM, O’Brien JT. A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. Int J Geriatr Psychiatry 2014;29:551-61. Crossref
12. Schöll M, Damián A, Engler H. Fluorodeoxyglucose PET in neurology and psychiatry. PET Clin 2014;9:371-90. Crossref
13. Vandenberghe R, Adamczuk K, Dupont P, Laere KV, Chételat G. Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer’s disease. Neuroimage Clin 2013;2:497-511. Crossref
14. Cummings JL. Biomarkers in Alzheimer’s disease drug development. Alzheimers Dement 2011;7:e13-44. Crossref
15. Ossenkoppele R, Prins ND, Pijnenburg YA, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 2013;9:414-21. Crossref
16. Laforce R Jr, Buteau JP, Paquet N, Verret L, Houde M, Bouchard RW. The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: A retrospective memory clinic study. Am J Alzheimers Dis Other Demen 2010;25:324-32. Crossref
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939-44. Crossref
18. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60. Crossref
19. Waldö ML. The frontotemporal dementias. Psychiatr Clin North Am 2015;38:193-209. Crossref
20. Shea YF, Ha J, Chu LW. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic. Psychogeriatrics 2014;15:235-41. Crossref
21. Zweig YR, Galvin JE. Lewy body dementia: the impact on patients and caregivers. Alzheimers Res Ther 2014;6:21. Crossref
22. Gauthier S. Pharmacotherapy of Parkinson disease dementia and Lewy body dementia. Front Neurol Neurosci 2009;24:135-9. Crossref
23. Baborie A, Griffiths TD, Jaros E, et al. Frontotemporal dementia in elderly individuals. Arch Neurol 2012;69:1052-60. Crossref
24. Hornberger M, Piguet O. Episodic memory in frontotemporal dementia: a critical review. Brain 2012;135:678-92. Crossref
25. Portugal Mda G, Marinho V, Laks J. Pharmacological treatment of frontotemporal lobar degeneration: systematic review. Rev Bras Psiquiatr 2011;33:81-90. Crossref
26. Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci 2015;36:297-309. Crossref
27. Wisniewski T, Goñi F. Immunotherapeutic approaches for Alzheimer’s disease. Neuron 2015;85:1162-76. Crossref
28. Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA 2014;312:2551-61. Crossref
29. Kovacs GG. Tauopathies. In: Kovacs GG, editor. Neuropathology of neurodegenerative diseases: a practical guide. Cambridge: Cambridge University Press; 2015: 125-8.